Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Ursodeoxycholic acid (UDCA) treatment has been shown to increase survival without orthotopic liver transplantation (OLT) in patients with primary biliary cirrhosis (PBC) at 4 years. Whether this beneficial effect was maintained over the long term remained to be established. In a large cohort of UDCA–treated patients with PBC, we aimed to determine the 10–year outcome of these patients using two endpoints: (1) survival without OLT, and (2) survival. The cohort was comprised of 225 patients with PBC treated with UDCA (13–15 mg/kg/d) monitored from the beginning of treatment until time of last follow–up, OLT, or death. Because of the absence of a control group, survival without OLT was compared with survival predicted by the Mayo model (first 7 years), and observed 10–year survival with an estimation of survival of a standardized control cohort of the French population. Observed survival without OLT of UDCA–treated patients was significantly higher (P < .04) than survival predicted by the Mayo model. Observed survival was significantly lower (P < .01) than survival predicted from the French population. Observed survival of noncirrhotic patients was not different (P > .9) from that of the French control population but survival of cirrhotic patients was significantly lower (P < .0001). Twenty–two patients died; 13 patients died of hepatic causes and 4 patients died after OLT. In conclusion, survival without OLT among patients treated with UDCA for PBC is higher than that of untreated patients, as predicted by the Mayo model. Ten–year survival among UDCA–treated patients is slightly lower than that of an age– and sex–matched general population, the difference mainly being explained by mortality among cirrhotic patients
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Advanced histological stages are consistently associated with a poor prognosis in PBC [93,94,47,63,95].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [94]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Self-citationStaging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)
Ludwig, J., Dickson, E. R., & McDonald, G. S. A. (1978) · Virchows Archiv A Pathological Anatomy and Histology · doi:10.1007/bf00432479 · Cited by 753
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746
Self-citationPoupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648
Self-citationUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUrsodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487 · cited 5×
“To compare survival of patients under UDCA treatment with survival in the general French population a standardized control cohort was constructed as follows: (1) the actual recorded number of deaths in the French population gave us the average probability of death according to age and gender from 1982 to 1994, (2) for…”
BackgroundMethodInfluentialCOMBES, B. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 268
Research works printed but not linked: 2
- Combes, 1995, A randomized, double-blind, placebo-controlled trial of ursodeoxycholate in primary biliary cirrhosis, Hepatology, 22, 759
- Poupon, 1997, Bile acids and Immunology, 241
Cited by
Items 101–200 of 213
Latest and Emerging Therapies for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis
Zein, C. O., & Lindor, K. D. (2010) · Current Gastroenterology Reports · doi:10.1007/s11894-009-0079-2 · Cited by 26
Koulentaki, M., Moscandrea, J., Dimoulios, P., Chatzicostas, C., & Kouroumalis, E. (2004) · Digestive Diseases and Sciences · doi:10.1023/b:ddas.0000037811.48575.da · Cited by 25
An update on the management of cholestatic liver diseases
Appanna, G., & Kallis, Y. N. (2020) · Clinical Medicine · doi:10.7861/clinmed.2020-0697 · Cited by 23
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Poupon, R. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0107 · Cited by 25
Self-citationIrie, M., KOUDA, M., & Matono, H. (2011) · Journal of Animal Science · doi:10.2527/jas.2011-4211 · Cited by 24
The mystery of primary biliary cirrhosis in British Columbia’s First Nations people
Arbour, L. T., Field, L., Ross, P. J., Erikson, A., & Yoshida, E. M. (2004) · International Journal of Circumpolar Health · doi:10.3402/ijch.v63i0.17896 · Cited by 22
Update on pharmacotherapies for cholestatic liver disease
Ali, A. H., Tabibian, J. H., & Lindor, K. D. (2016) · Hepatology Communications · doi:10.1002/hep4.1013 · Cited by 22
The unfolded protein response in hereditary haemochromatosis
de Almeida, S. F., & de Sousa, M. A. B. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00179.x · Cited by 25
Kanda, T., Sasaki, R., Kimura, N., Abé, H., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., Tsuchiya, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051883 · Cited by 22
Roda, E., Azzaroli, F., Nigro, G., Piazza, F., Jaboli, F., Ferrara, F., Liva, S., Giovanelli, S., Miracolo, A., Colecchia, A., et al. (2002) · Digestive and Liver Disease · doi:10.1016/s1590-8658(02)80112-8 · Cited by 19
Hepatic Fibrosis and Cirrhosis
Rockey, D. C., & Friedman, S. L. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50011-5 · Cited by 36
Primary biliary cirrhosis and liver transplantation
Akamatsu (2012) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2012.v1.2.66 · Cited by 26
Emerging drugs for the treatment of Primary Biliary Cholangitis
Ali, A. H., Tabibian, J. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1150999 · Cited by 19
“population.[26] However, a significant proportion of PBC”
ResultRisk stratification and prognostic modelling in primary biliary cholangitis
Goet, J. C., Harms, M. H., Carbone, M., & Hansen, B. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.006 · Cited by 19
Modulating Proteostasis: Peptidomimetic Inhibitors and Activators of Protein Folding
Hatahet, F., & Ruddock, L. W. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788682343 · Cited by 18
Sepe, V., Ummarino, R., D’Auria, M. V., Taglialatela‐Scafati, O., Marino, S. D., D’Amore, C., Renga, B., Chini, M. G., Bifulco, G., Nakao, Y., et al. (2012) · Marine Drugs · doi:10.3390/md10112448 · Cited by 18
“Cholestasis, a liver disease, represents the main biochemical feature of primary biliary cirrhosis [26,27] (PBC) and sclerosing cholangitis (PSC), two immune-mediated disorders characterized by progressive bile duct destruction for which medical therapy is still insufficiently effective and where investigations are on…”
BackgroundThe pyruvate dehydrogenase complex as a target autoantigen in primary biliary cirrhosis
Nishio, A., Coppel, R. L., Ishibashi, H., & Gershwin, M. E. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0102 · Cited by 18
Primary biliary cirrhosis: From bench to bedside
Kouroumalis, E., & Notas, G. (2015) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v6.i3.32 · Cited by 21
Improving prognosis in primary biliary cholangitis – Therapeutic options and strategy
Harms, M. H., van Buuren, H. R., & van der Meer, A. J. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.004 · Cited by 18
Setchell, K. D. R., Galzigna, L., O’Connell, N. C., Brunetti, G., & Tauschel, H. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02385.x · Cited by 15
Durchschein, F., Krones, E., Pollheimer, M. J., Zollner, G., Wagner, M., Raufman, J., & Fickert, P. (2017) · Hepatology Research · doi:10.1111/hepr.12928 · Cited by 17
Treatment of primary biliary cirrhosis
Szalay, F. (2001) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(01)00055-9 · Cited by 14
Clinical Studies With Silymarin: Fibrosis Progression Is the End Point
Schuppan, D., & Hahn, E. G. (2001) · Hepatology · doi:10.1002/hep.510330230 · Cited by 14
Hepatic Fibrosis and Cirrhosis
Rockey, D. C., & Friedman, S. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00005-x · Cited by 22
Melchor-Mendoza, Y. K., Martínez‐Benítez, B., Mina, A., Rodríguez-Leal, G. A., Duque, X., & Morán, S. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0009.8598 · Cited by 13
Cirrosis biliar primaria: experiencia de trece años en dos centros de referencia
Valera, J. M., Gladys Smok, S., Jaime Poniachik, T., Danny Oksenberg, R., Guillermo Silva, P., Ferrario, M., Erwin Buckel, G., & Javier Brahm, B. (2006) · Revista médica de Chile · doi:10.4067/s0034-98872006000400010 · Cited by 16
Jung, H. E., Jang, J. Y., Jeong, S. W., Kim, J. N., Jang, H. Y., Cho, Y. J., Woo, S. A., Lee, S. H., Kim, S. G., Cha, S., et al. (2012) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2012.18.4.375 · Cited by 12
Current Therapies for Cholestatic Diseases
Méndez‐Sánchez, N., Coronel-Castillo, C. E., & Ordóñez-Vázquez, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11061713 · Cited by 12
Lazaridis, K. N., & Lindor, K. D. (1999) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-999-0051-0 · Cited by 12
Management of primary biliary cirrhosis resistant to ursodeoxycholic acid therapy
Poupon, R. Y. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80438-9 · Cited by 12
Self-citationMedical and economic impact of autoimmune hepatitis
Talwalkar, J. A., & Kim, W. R. (2002) · Clinics in Liver Disease · doi:10.1016/s1089-3261(02)00030-2 · Cited by 10
Automated Enzymatic Mitochondrial Antibody Assay for the Diagnosis of Primary Biliary Cirrhosis
Jensen, W. A., Jois, J. A., Murphy, P., Giorgio, J. D., Brown, B., Rowley, M. J., & Mackay, I. R. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.107 · Cited by 10
Abbas, N., Smith, R. A., Lytvyak, E., Scraravaglio, M., Halliday, N., Almahroos, A., Eden, N., Lloyd‐Madden, D., Sharma, S., Ferguson, J., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70378 · Cited by 9
Hopf, C., Grieshaber, R., Hartmann, H., Hinrichsen, H. M., Eisold, M., Cordes, H.-J., Greinwald, R., & Rust, C. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.24 · Cited by 9
Muriel, P., Vargas-Pozada, E. E., Márquez-Quiroga, L. V., & Ramos‐Tovar, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062546 · Cited by 8
“In a meta-analysis, Shi et al. reported that UDCA, despite improving serum markers of liver damage, had no beneficial effects on hepatic histology or survival in treated patients compared with the placebo group [127].”
HEPATOLOGY IN THE NEW MILLENNIUM
Ramrakhiani, S., & Bacon, B. R. (2000) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70277-7 · Cited by 8
Duclos‐Vallée, J., Martino, V. D., Cazier, A., Ballot, E., Johanet, C., Yamamoto, A., Emile, J., Guettier, C., Coutarel, P., & Cadranel, J. (2005) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(05)82185-2 · Cited by 8
Primär biliäre Leberzirrhose und Overlap-Syndrome
Strassburg, C. P., & Manns, M. P. (2004) · Der Internist · doi:10.1007/s00108-003-1127-x · Cited by 8
Herold, C., Ganslmayer, M., Deynet, C., Hahn, E. G., & Schuppan, D. (2002) · Liver International · doi:10.1034/j.1600-0676.2002.01641.x · Cited by 8
A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis
Wang, L., Guo, G., Wang, J., Zhou, X., Yang, Q., Han, Z.-Y., Li, Q., Zhang, J., Cai, Y., Ren, X., et al. (2015) · Scientific Reports · doi:10.1038/srep09772 · Cited by 8
Primary biliary cholangitis: new treatments for an old disease
Trivedi, H. D., Lizaola‐Mayo, B., Tapper, E. B., & Bonder, A. (2016) · Frontline Gastroenterology · doi:10.1136/flgastro-2016-100741 · Cited by 7
Novel Therapies in Primary Biliary Cholangitis
Buchanan-Peart, K.-A., & Levy, C. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.013 · Cited by 7
Review: Current status of therapy in autoimmune liver disease
Hirschfield, G. M., Al‐Harthy, N., & Heathcote, E. J. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08098966 · Cited by 7
“French cohorts with long-term follow-up similarly demonstrate survival benefit [Poupon et al. 1999; Corpechot et al. 2005] and this was reiterated by a Spanish cohort including nearly 200 patients treated for a mean of 6.7 years [Pares et al. 2006].”
BackgroundInfluentialBone involvement in patients with chronic cholestasis
Gars, L. L. (2002) · Joint Bone Spine · doi:10.1016/s1297-319x(02)00413-x · Cited by 7
Ishibashi, H., Nakanuma, Y., Ueno, Y., Egawa, H., Koike, K., Komori, A., Sakisaka, S., Shimoda, S., Shirabe, K., Zeniya, M., et al. (2012) · Kanzo · doi:10.2957/kanzo.53.633 · Cited by 7
Noninvasive Evaluation of Fibrosis and Portal Hypertension in Primary Biliary Cholangitis
Corpechot, C. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.010 · Cited by 6
Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies—A Critical Overview
Kasztelan‐Szczerbińska, B., Rycyk, A., Szczerbińska, A., & Cichoż‐Lach, H. (2023) · Nutrients · doi:10.3390/nu15030760 · Cited by 6
“Ten-year survival among UDCA-treated PBC patients is slightly lower than in the general population [178].”
BackgroundNew Therapies in Hepatitis C Virus and Chronic Liver Disease: Antifibrotics
Rockey, D. C. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2006.08.019 · Cited by 7
Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis
van Buuren, H. R., Lammers, W. J., Harms, M. H., & Hansen, B. E. (2015) · Digestive Diseases · doi:10.1159/000440759 · Cited by 10
Genetics of Hepatobiliary Diseases
Juran, B. D., & Lazaridis, K. N. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.03.004 · Cited by 7
van Hooff, M. C., de Veer, R. C., Karam, V. H., Adam, R. A., Taimr, P., Polak, W. G., Pashtoun, H., Murad, S. D., Corpechot, C., Mirza, D. F., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101100 · Cited by 5
Clark, V., & Levy, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_3 · Cited by 5
An update on novel investigational agents for the treatment of primary biliary cholangitis
Floreani, A., Gabbia, D., & Martin, S. D. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2573638 · Cited by 4
Lee, S., Belyaeva, O. V., & Kedishvili, N. Y. (2011) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2011.01.001 · Cited by 4
Chemical chaperone-conjugated exendin-4 as a cytoprotective agent for pancreatic β-cells
Son, S., Park, E. J., Kim, Y., Lee, K. C., & Na, D. H. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.09.018 · Cited by 4
38-Year-Old Woman With Abnormal Liver Enzymes and Hyperlipidemia
Silveira, M. G., & Lindor, K. D. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.6.551 · Cited by 4
Talwalkar, J. A., & Lindor, K. D. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50046-2 · Cited by 4
Carlisle, R. E., Farooqi, S., Zhang, M. C., Liu, S., Lü, C., Phan, A., Brimble, E., & Dickhout, J. G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260519 · Cited by 4
Milkiewicz, P., & Heathcote, J. (2006) · Wiley eBooks · doi:10.1002/9780470986981.ch21 · Cited by 4
Management of Patients with Primary Biliary Cirrhosis: A Practical Guide
Nishio, A., Neuberger, J., & Gershwin, M. E. (1999) · BioDrugs · doi:10.2165/00063030-199912030-00001 · Cited by 4
“BioDrugs 1999 Sep; 12 (3) Lindor et al.[68]* 180 13 to 15 mg/kg 1-4 years No improvement Improved No improvement None None Lindor et al.[69]c 180 3-1 mg/kg 0.5-7 years No improvement Improved No improvement None Decreased Poupon et al.[66]* 146 13–15 mg/kg 2 years Improved Improved Improved (except fibrosis) None None…”
BackgroundInfluentialDíaz‐González, Á., Molera, C., Gómez-Domínguez, E., Muñoz‐Bartolo, G., Ampuero, J., Fernández‐Rodríguez, C., Quintero, J., Molina, E., Salcedo, M., Olveira, A., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2026.502629 · Cited by 3
Sherlock, F. S., & BSc, J. D. (2001) · Wiley eBooks · doi:10.1002/9780470986820.ch14 · Cited by 3
Yoshida, E. M. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001999 · Cited by 2
Zaman, A. (2006) · Evidence-Based Gastroenterology · doi:10.1097/01.ebg.0000202916.43066.ec · Cited by 2
Poupon, R. Y. (2010) · EMC - Hépatologie · doi:10.1016/s1155-1976(10)46408-6 · Cited by 5
Self-citation[Advances in the treatment of primary biliary cholangitis].
Li, Y. M., Wang, Q. X., & Ma, X. (2017) · PubMed Central · doi:10.3760/cma.j.issn.1007-3418.2017.11.002 · Cited by 2
Management chronischer Hepatopathien - State of the art 2003
Stauber, R. E. (2003) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 2
Poupon, R. Y. (2010) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(10)54652-0 · Cited by 2
Self-citationLi, J., Fang, P., Luo, A., Xu, L., Luo, T., Han, J., Li, T., Qi, X., Cheng, S., Huo, H., et al. (2026) · Animal Feed Science and Technology · doi:10.1016/j.anifeedsci.2026.116782 · Cited by 1
Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Other Cholestatic Liver Diseases
Zein, C. O. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6643-9.00081-3 · Cited by 1
11. Primary Biliary Cirrhosis: Recent Progress and Unsolved Questions
Ueno, Y. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.2300 · Cited by 1
Autoimmune hemolytic anemia as a complication of primary biliary cirrhosis.
Cr, D. M., & Setubal, D. C. (2004) · PubMed · Cited by 1
Parés, A. R. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_35 · Cited by 1
Primary Biliary Cholangitis: Its Science and Practice
Wang, L., Bowlus, C. L., Wang, F., & Gershwin, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50168-0_8 · Cited by 2
[Primary biliary cholangitis and bile acid metabolism].
Wang, L., Han, Y. C., & Han, Y. (2017) · PubMed · doi:10.3760/cma.j.issn.1007-3418.2017.11.015 · Cited by 1
Hepatotoxicidade induzida por medicamento em um paciente ambulatorial: relato de caso
Prado, N. M. D. B. L., Messias, G. C., Santos, G., & Paraná, R. (2019) · Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde · doi:10.30968/rbfhss.2018.091.004 · Cited by 1
Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective
Gao, W., Li, Z., Chu, H., Yuan, H., Hu, L., Yao, L., Zhang, L. R., Wang, W., Lin, R., & Yang, L. (2022) · Springer eBooks · doi:10.1007/978-981-19-2615-0_6 · Cited by 1
Case 4-2023: A 56-Year-Old Man with Abnormal Results on Liver Testing
Bhan, I., Schaefer, E. A. K., Bradley, W. R., Rodriguez‐Lopez, J., Crowley, J., & Hutchison, B. M. (2023) · New England Journal of Medicine · doi:10.1056/nejmcpc2201249 · Cited by 1
Poupon, R. Y. (2010) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(10)70489-x · Cited by 1
Self-citationDrug therapy of primary biliary diseases: classical and modern strategies
Schlichting, J., & Leuschner, U. (2001) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2001.tb00144.x · Cited by 1
“In a recently published long term trial the ten years survival on UDCA in 225 patients was higher than that of untreated patients as predicted by the Mayo model [35].”
ResultAutoimmune Liver Diseases in Canterbury, New Zealand
Ngu, J. H. (2013) · Otago University Research Archive (University of Otago) · Cited by 2
Erkrankungen von Leber, Gallenwegen und Pankreas
Mössner, J., Stremmel, W., Gerken, G., Jochum, C., Strassburg, C. P., Vogel, A., Manns, M. P., Grothe, W., Fleig, W. E., Pape, U., et al. (2003) · Springer eBooks · doi:10.1007/978-3-662-12451-2_10
Dancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_19
Poupon, R. Y. (2011) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(11)70560-5
Self-citationL’atteinte osseuse dans les maladies chroniques cholestatiques
Gars, L. L. (2002) · Revue du Rhumatisme · doi:10.1016/s1169-8330(02)00369-1
Efficacy of Ursodeoxycholic Acid in Chinese Patients with End-Stage Primary Biliary Cirrhosis
Wan, Y., Yang, L., Jun-Hui, Y., Xu, Y., Jing, Y., Tang, Y., Zhiyuan, X., Li, Y., Li, Y., Yu, C., et al. (2014) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2014.03.467
Treatment of primary biliary cirrhosis
Poupon, R. Y., & Corpechot, C. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.870031
“Several independent cohort analyses showed that long-term survival in UDCA-treated patients with PBC (13 -- 15 mg/kg/day) was significantly longer than expected from natural history models of the disease [78-81].”
BackgroundSelf-citationOnji, M., Al‐Mahtab, M., Akbar, S. M. F., Chen, S., Abe, M., Yoshida, O., Ikeda, Y., & Hiasa, Y. (2012) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1028
La cirrhose biliaire primitive : actualités
Corpechot, C. (2013)
Liver Transplantation for Primary Biliary Cirrhosis
Talwalkar, J. A., Kim, W. R., & Dickson, E. R. (2005) · Elsevier eBooks · doi:10.1016/b978-0-7216-0118-2.50017-3
Boberg, K. M. (2009) · NORA - Norwegian Open Research Archives
Medical Therapy of Cholestatic Liver Diseases
Rust, C., & Beuers, U. H. (2010) · Springer eBooks · doi:10.1007/978-1-4419-9034-1_24
Features, prognosis and management of primary biliary cirrhosis in the era of ursodeoxycholic acid
Poupon, R. Y., Chazouillères, O., Chrétien, Y., & Corpechot, C. (2009) · Springer eBooks · doi:10.1007/978-1-4020-9644-0_37
Self-citationCarey, E. J., Rakela, J. L., & Vargas, H. E. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-0268-8.00036-1
Targets and investigative treatments for primary biliary cholangitis
Ali, A. H., Carey, E. J., & Lindor, K. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1227240
“The survival of patients with non-cirrhotic PBC who respond to UDCA is similar to that of the healthy population [28].”
BackgroundMyers, R. P. (2008) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/21267
Therapy of primary biliary cirrhosis
Poupon, R. Y., Corpechot, C., & Poupon, R. E. (2000) · Springer eBooks · doi:10.1007/978-94-011-4000-3_28
Self-citationHamczyk, M. R. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Liver Cirrhosis with Autoimmune Liver Diseases: AIH and PBC
Abe, K., Takahashi, A., & Ohira, H. (2019) · Springer eBooks · doi:10.1007/978-981-13-7979-6_2
Regulation of Endoplasmic Reticulum Stress in Saccharomyces cerevisiae
Chadwick, S. R. (2020) · Scholarship@Western (Western University)
Metadata
- Authors
- Poupon, R. E., Bonnand, A.-M., Chrétien, Y., & Poupon, R.
- Affiliations
- Inserm (FR)
- Corresponding author
- Poupon, Renée Eugénie
- ORCID
- Poupon, Raoul
- Venue
- Hepatology
- Published
- 1999-06
- Volume
- 29
- Issue
- 6
- Pages
- 1668-1671
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2048473231
- Semantic Scholar
- 99291208dd4bc0b499ad3d29ef6c903d615daa5d
- Cited by
- 209
- References
- 19
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 3 · 2020: 6 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 8 · 2014: 11 · 2013: 6 · 2012: 11
- FWCI
- 6.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 5936 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- PHRC, Assistance Publique-Hôpitaux de Paris (AOM 96045)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, long-term survival, liver transplantation, Mayo risk score, mortality, cirrhotic patients, non-cirrhotic patients, bile acid therapy
- MeSH terms
- Bilirubin, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Prothrombin Time, Serum Albumin, Time Factors, Ursodeoxycholic Acid, Cohort Studies, Survival Analysis, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.